Literature DB >> 22502704

5'-CpG island promoter hypermethylation of the CAV-1 gene in breast cancer patients of Kashmir.

Nidda Syeed1, Firdous Hussain, Syed Akhtar Husain, Mushtaq A Siddiqi.   

Abstract

BACKGROUND: Caveolin-1 (CAV-1), encoding the structural component of cellular caveolae, is a suggested tumor suppressor gene involved in cell signalling. Aberrant promoter methylation of CAV-1 is associated with inactivation of expression. We previously observed CAV-1 mutations in breast cancers and therefore devised this study to examine the hypermethylation status of the promoter region of CAV-1 with reference to breast cancer progression and development.
METHODS: Hypermethylation status of CAV-1 was analyzed by methylation specific PCR. Loss of expression of the CAV-1 gene was further evaluated by semi-quantitative rt-PCR.
RESULTS: 28/130 (21.5%) breast cancer cases showed promoter hypermethylation with reduced CAV-1 expression levels when compared with adjacent normal breast tissue. CAV-1 gene hypermethylation was significantly related to menopausal status, histopathological grade and age.
CONCLUSION: The rationale of our study is that CAV-1 gene is transcriptionally repressed in breast cancer cells due to hypermethylation. Our results reveal that promoter hypermethylation and loss of expression of the CAV-1 gene is an important alternative mechanism for inactivation of CAV-1 leading to complete gene silencing.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22502704     DOI: 10.7314/apjcp.2012.13.1.371

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  8 in total

1.  Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.

Authors:  Carlotta Borsoi; Fransisca Leonard; Yeonju Lee; Mohamed Zaid; Dalia Elganainy; Jenolyn Francisca Alexander; Megumi Kai; Yan Ting Liu; Yaan Kang; Xuewu Liu; Eugene J Koay; Mauro Ferrari; Biana Godin; Kenji Yokoi
Journal:  Cancer Lett       Date:  2017-07-04       Impact factor: 8.679

2.  Cav1 inhibits benign skin tumor development in a two-stage carcinogenesis model by suppressing epidermal proliferation.

Authors:  Casey Trimmer; Federica Sotgia; Michael P Lisanti; Franco Capozza
Journal:  Am J Transl Res       Date:  2013-01-21       Impact factor: 4.060

3.  Viral interleukin-6 encoded by an oncogenic virus promotes angiogenesis and cellular transformation by enhancing STAT3-mediated epigenetic silencing of caveolin 1.

Authors:  Wan Li; Qingxia Wang; Xiaoyu Qi; Yuanyuan Guo; Hongmei Lu; Yuheng Chen; Zhongmou Lu; Qin Yan; Xiaofei Zhu; Jae U Jung; Giovanna Tosato; Shou-Jiang Gao; Chun Lu
Journal:  Oncogene       Date:  2020-05-11       Impact factor: 9.867

Review 4.  Epigenetic modifications of caveolae associated proteins in health and disease.

Authors:  Jin-Yih Low; Helen D Nicholson
Journal:  BMC Genet       Date:  2015-06-26       Impact factor: 2.797

5.  Identification of diagnostic markers in colorectal cancer via integrative epigenomics and genomics data.

Authors:  Teow Kok-Sin; Norfilza Mohd Mokhtar; Nur Zarina Ali Hassan; Ismail Sagap; Isa Mohamed Rose; Roslan Harun; Rahman Jamal
Journal:  Oncol Rep       Date:  2015-05-19       Impact factor: 3.906

6.  Expression of Caveolin 1 is enhanced by DNA demethylation during adipocyte differentiation. status of insulin signaling.

Authors:  Sara Palacios-Ortega; Maider Varela-Guruceaga; Fermín Ignacio Milagro; José Alfredo Martínez; Carlos de Miguel
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

Review 7.  Molecular regulation and clinical significance of caveolin-1 methylation in chronic lung diseases.

Authors:  Furong Yan; Lili Su; Xiaoyang Chen; Xiangdong Wang; Hongzhi Gao; Yiming Zeng
Journal:  Clin Transl Med       Date:  2020-04-16

8.  Value of caveolin-1 in cancer progression and prognosis: Emphasis on cancer-associated fibroblasts, human cancer cells and mechanism of caveolin-1 expression (Review).

Authors:  Dali Chen; Guowei Che
Journal:  Oncol Lett       Date:  2014-07-28       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.